Résumé
Chez les patients obèses les paramètres pharmacologiques des antibiotiques sont modifiés, une adaptation des posologies est ainsi nécessaire afin d’éviter la survenue d’échec thérapeutique et d’émergence de bactéries résistantes. L’objectif de ce travail est de faire le point sur la pharmacologie des antibiotiques chez les sujets obèses.
Abstract
Among obese patients antibiotics pharmacological parameters are modified, a dose adaptation is so necessary to avoid the arisen of therapeutic failure and emergence of resistant bacteria. The objective of this work is to review the pharmacology of antibiotics to the obese subjects.
Article PDF
Avoid common mistakes on your manuscript.
Références
Finucane MM, Stevens GA, Cowan MJ, et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 377: 557–67
Population Référence bureau (http://www.prb.org/pdf08/08WPDS_FR.pdf)
Ogden CL, Ogden CL, Carroll MD et al (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311: 806–14
Enquête épidémiologique nationale sur le surpoids et l’obésité, http://www.roche.fr/content/dam/corporate/roche_fr/doc/obepi_2012.pdf
Falagas ME, Karageorgopoulos DE (2010) Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375: 248–51
Conterweight Project Team (2005) The impact of obesity on drug prescribing in primary care. Br J Gen Pract 519: 743–9
Longo C, Bartlett G, Macgibbon B, et al (2013) The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 9: 970–6
Wolf AM, Wolf D, Rumpold H, et al (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323: 630–5
Faggioni R, Feingold KR, Grunfeld C. (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 14: 2565–71
Dossett LA, Dageforde LA, Swenson BR, et al (2009) Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect (Larchmt) 2: 137–42
Villar-Compte D, Mohar A, Sandoval S, et al (2000) Surgical site infections at the National Cancer Institute in Mexico: a casecontrol study. Am J Infect Control 1: 14–20
Kornum JB, Nørgaard M, Dethlefsen C, et al (2010) Obesity and risk of subsequent hospitalisation with pneumonia. Eur Respir J 6: 1330–6
Vaillant L, La Ruche G, Tarantola A, et al (2009) Epidemiology of fatal cases associated with pandemic H1N1 influenzae 2009. Euro surveill 14: 33
Center for Disease Conrol and Prevention (CDC) (2009) Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1). MMWR Morb Mortal Wkly Rep. 38: 1071–74
Roujeau JC (2001) Necrotizing fasciitis. Clinical criteria and risk factors. Ann Dermatol Venereol 128: 376–81
Rouquette-Vincenti I, Petitjeans F, Villevieille T, et al (2001) Obesity, diabetes mellitus, and gas gangrene: a major therapeutic challenge. Ann Endocrinol 6: 525–8
Guillemot D, Carbon C, Balkau B, et al (1998) Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 5: 365–70
Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8: 650–5
Bearden DT, Rodvold KA (2000) Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 5: 415–26
Knibbe CA, Brill MJ, van Rongen A, et al (2015) Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 55: 149–67
Jackson SJ, Leahy FE, McGowan AA, et al (2004) Delayed gastric emptying in the obese: an assessment using the non invasive (13)-C-octanoic acid breath test. Diab Obes Metab 6: 264–70
Leykin Y, Miotto L, Pellis T (2011) Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol 25: 27–36
Lloret Linares C, Declèvres X, Bergmann JF (2013) Pharmacocinétique des médicaments chez les sujets obèses mt 19: 215–28
Boulamery Velly A, Simon N, Bruguerole B (2006) Pharmacokinetic characteristics in obese patients. Réanimation 15: 427–32
Aggarwal N, Porter AC, Tang IY (2012) Creatinine based estimations of kidney function are unreliable in kidney donors. J Transplant 872–94
Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 4: 289–300
Erstad BL (2004) Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 30: 18–32
Zakrison TL, Hille DA, Namias N (2012) Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillintazobactam. Surg Infect (Larchmt) 13: 38–42
Deman H, Verhaegen J, Willems L, et al (2012) Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother 67: 782–3
Forse RA, Karam B, MacLean LD, et al (1989) Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106: 750–6
Itani KM, Jensen EH, Finn TS, et al (2008) Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) 9: 131–7
Rich BS, Keel R, Ho VP, et al (2012) Cefepime dosing in the morbidly obese patient population. Obes Surg 22: 465–71
Hites M, Taccone FS, Wolff F, et al (2014) Broad-spectrum ß-lactams in obese non-critically ill patients. Nutr Diabetes 4: 119
Mann HJ, Buchwald H (1986) Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 20: 869–73
Evans JD, Udeani G, Cole P, et al (2014) Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients. Postgrad Med 126: 128–34
Chen M, Nafziger AN, Drusano GL, et al (2006) Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50: 1222–7
Zakrison TL, Hille DA, Namias N (2012) Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillintazobactam. Surg Infect (Larchmt) 13: 38–42
Kays MB, Fleming MR, Cheatham SC, et al (2014) Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother 48: 178–86
Cheatham SC, Fleming MR, Healy DP, et al (2014) Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 54: 324–30
Pea F, Cojutti P, Sbrojavacca R, et al (2011) TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 45: 37
Taccone FS, Cotton F, Roisin S, et al (2012) Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56: 2129–31
http://ansm.sante.fr/Dossiers/Antibiotiques/Autres-recommandations-impliquant-des-antibiotiques/(offset)/8
Cook AM, Martin C, Adams VR, et al (2011) Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother 55: 3240–3
Luque S, Grau S, Valle M et al (2011) Levofloxacin weightadjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 66: 1653–4
Allard S, Kinzig M, Boivin G, et al (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54: 368–73
Utrup TR, Mueller EW, Healy DP, et al (2010) High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother 44: 1660–4
Kees MG, Weber S, Kees F, et al (2011) Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 66: 2330–5
Bauer LA, Black DJ, Lill JS (1998) Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 54: 621–5
Richardson J, Scheetz M, O’Donnell EP (2015) The association of elevated trough serum vancomycin concentrations with obesity. J Infect Chemother 21: 507–11
Lodise TP, Patel N, Lomaestro BM, et al (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49: 507–14
Abdullahi M, Annibale B, Capoccia D, et al (2008) The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 18: 1450–4
Cerqueira RM, Manso MC, Correia MR, et al (2011) Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery—fourteen days superior to seven days? Obes Surg 21: 1377–81
Bhalodi AA, Papasavas PK, Tishler DS, et al (2013) Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 57: 1144–9
Stein GE, Schooley SL, Peloquin CA, et al (2005) Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 39: 427–32
Corcione S, Pagani N, Baietto L, et al (2015) Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. J Antimicrob Chemother 70: 2417–8
Dvorchik BH, Damphousse D (2005) The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 45: 48–56
Klibanov OM, Vickery S, Nortey C (2014) Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient. Ann Pharmacother 48: 652–5
Pai MP (2014) Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother 69: 190–9
Bulik CC, Wiskirchen DE, Shepard A, et al (2010) Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 54: 5209–13
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mellon, G. Obésité et antibiothérapie. Obes 11, 200–205 (2016). https://doi.org/10.1007/s11690-016-0520-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11690-016-0520-2